LAEKNA-B(02105): The first subject has been dosed in the Phase I single dose escalation study of LAE103.

LAEKNA-B (02105) announced that the group has initiated subject enrollment for the Phase I single-dose escalation study (SAD study) of LAE103 (a self-developed ActRIIB monoclonal antibody) in Australia. As of the date of this announcement, the first subject has completed dosing. The SAD study is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics of LAE103 (subcutaneous injection) in healthy overweight or obese subjects. The group aims to announce the topline data of this SAD study in the third quarter of 2026. The group is committed to bringing this precision therapy into areas of significant unmet medical needs in cardiovascular and metabolic diseases, such as obesity, muscular dystrophy, and heart failure.